Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Open Access
- 1 August 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (3) , 961-965
- https://doi.org/10.1182/blood-2002-02-0408
Abstract
We evaluated the clinical characteristics of 41 children with chronic neutropenia based on the quantitative analysis of antineutrophil antibodies in serum by flow cytometry. According to the strength of antineutrophil antibodies, the patients were divided into 3 groups: 12 patients presented negative antibodies, 13 patients showed weak positive antibodies, and 16 patients showed strong positive antibodies. No significant differences were seen in age of diagnosis, severity of neutropenia, and infectious complications associated with neutropenia among the 3 groups. The spontaneous resolution of neutropenia was observed in all patients with negative antibodies and in 22 of 29 patients with positive antibodies. The age of the recovery of neutropenia and the duration until spontaneous resolution of neutropenia were significantly dependent on the antibody strength at the time of diagnosis. These results demonstrate that the quantification of antineutrophil antibodies at the time of diagnosis may be useful in considering the clinical course of chronic neutropenia in childhood.Keywords
This publication has 21 references indexed in Scilit:
- Sperm protein 17 is a novel cancer-testis antigen in multiple myelomaBlood, 2001
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesBlood, 2000
- Expression of testicular genes in haematological malignanciesBritish Journal of Cancer, 1999
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myelomaInternational Journal of Cancer, 1999
- Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose ChemotherapyBlood, 1999
- Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility StudyBlood, 1999
- New Paths in Human Cancer SerologyThe Journal of Experimental Medicine, 1998
- Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell ResponsesBlood, 1998
- Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucinInternational Immunology, 1997
- Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasiasBlood, 1993